Predictive biomarkers inform therapeutic decisions by indicating the probable effect of a specific therapy on an individual. These biomarkers identify individuals who are more likely to experience positive or negative effects. Ace Therapeutics utilizes our expertise and platform technology to provide predictive biomarker development services for psychiatric disorders. Our integrated solutions will support clinical decision making and drive the development of personalized therapies for psychiatric disorders.

Introduction of Predictive Biomarkers

Predictive biomarkers are used to identify individuals who are more likely to respond to exposure to specific medical products or environmentally harmful substances. This response may be a symptomatic benefit, improved survival, or an adverse effect. The presence of these biomarkers with good predictive results may indicate the effectiveness of the new therapy due to the control therapy. Thus, the use of predictive biomarkers helps to select specific patients who are more likely to respond or not respond to treatment. In addition, trials with a biomarker strategy have a higher overall success rate compared to trials without biomarkers.

Our Preclinical Development Services for Predictive Biomarkers

Ace Therapeutics offers a robust approach to biomarker development to increase the chances of success. Below are the key steps we consider in predictive biomarker development for psychiatric disorders.

Predictive Biomarker Discovery

At Ace Therapeutics, our experienced experts identify potentially useful biomarkers through exploratory studies or retrospective analyses. Typically, for predictive biomarkers, the endpoint of interest is improvement in overall survival following drug therapy. We use in vitro cellular models and in vivo animal models to identify biomarkers with clinical utility.

Assay Development and Analytical Validation

The second step is to develop the assay so that the biomarker can be measured objectively. Subsequently, we perform analytical validation to ensure that the assay meets acceptable performance standards for sensitivity, selectivity, precision, accuracy, and reproducibility.

Our Assay Technologies

• Multiparametric flow cytometry
• Immunohistochemistry, high-throughput imaging/analysis and pathology
• Cytokine and chemokine analysis based on single and multiplex ELISA
• Genomic analysis based on high-sensitivity PCR, real-time PCR and NGS technologies
• Bioinformatics to guide biomarker discovery and validation, statistical analysis and preclinical studies
• Rare cell analysis for detection and monitoring of CTCs, CAR-T cells, etc.
• Complete blood count

Advantages of Us

• Data-driven: Relying on a large mental health database, we provide solid data support for biomarker development and validation.
• Advanced technology: We utilize genomics, transcriptomics, proteomics, metabolomics and other multi-omics technologies combined with bioinformatics tools to ensure the accuracy and timeliness of biomarker development.
• One-stop service: We provide one-stop service from biomarker discovery, validation to clinical application to help clients streamline the process and save time.

Ace Therapeutics is committed to applying our expertise to help our clients develop predictive biomarker strategies for psychiatric disorders as early as possible. Our services will help you select the best targets and models for preclinical studies in the development of therapies for psychiatric disorders. Please contact us for more details and we will be happy to assist you.